VGL-101 is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases. According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of VGL-101’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for VGL-101 is expected to reach an annual total of $49 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
VGL-101 Overview
Vigil Neuroscience Overview
Vigil Neuroscience is a biotechnology company that discovers and develops microglial therapeutics for the treatment of neurodegenerative diseases. The company is investigating its lead candidate VGL101, a fully human monoclonal antibody for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy (cALD) and Alzheimer’s disease. It is also evaluating small molecule term2 agonist, a microglial receptor protein targeting microangiopathies and Alzheimer’s disease. Vigil Neuroscience utilizes modern neuroscience drug development tools to develop precision-based therapies. The company works in collaboration with academic organizations, and pharmaceutical and biotechnology companies to develop its products. Vigil Neuroscience is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$68.9 million in FY2022, compared to an operating loss of US$42.4 million in FY2021. The net loss of the company was US$68.3 million in FY2022, compared to a net loss of US$43.3 million in FY2021.
For a complete picture of VGL-101’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
